In Vitro and In Vivo Amenability to Migalastat in Fabry Disease

Abstract excerpt

Migalastat (1-deoxygalactonojirimycin) is approved for the treatment of Fabry disease (FD) in patients with an amenable mutation. Currently, there are at least 367 amenable and 711 non-amenable mutations known, based on an in vitro good laboratory practice (GLP) assay. Recent studies demonstrated that in vitro amenability of mutations did not necessarily correspond to in vivo amenability of migalastat-treated...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carbohydrate Chemistry and Synthesis
• Share to Lysosomal Storage Disorders Research
• Share to Trypanosoma species research and implications